7 completed, 4 recruiting, 1 not yet recruiting. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Recruiting 4, Not yet recruiting 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Validation of Nanosensor Oxygen Measurement Nanosensor - MItochondrial Myopathies, Mitochondrial Disease | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 70 | 2025-01-02 | 2026-10-07 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels N-Acetylcysteine - Mitochondrial Disease | Phase 1 | Recruiting | Michio Hirano, MD | 18 | 2023-07-06 | 2026-01-23 |
| Applying pGz in Mitochondrial Disease Cardiopulmonary Exercise Testing, pGz Bed, Gentle Jogger - Mitochondrial Myopathies, Mitochondrial Diseases | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 90 | 2023-03-22 | 2025-11-10 |
| Validation of Oxygen Nanosensor in Mitochondrial Myopathy Nanosensor - Mitochondrial Myopathies, Mitochondrial Diseases | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 24 | 2023-01-17 | 2026-02-18 |
| L-Citrulline Dose Finding Safety Study in MELAS L-Citrulline - MELAS Syndrome | Phase 1 | Completed | Baylor College of Medicine | 10 | 2021-04-22 | 2024-06-26 |
| MABs Therapy m.3243A>G Mutation Carriers autologous mesoangioblasts - Mitochondrial Myopathies | Phase 1 | Completed | Maastricht University | 6 | 2020-03-01 | 2024-01-17 |
| A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease KL1333, Placebo Oral Tablet - Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies | Phase 1 | Completed | Abliva AB | 72 | 2019-03-18 | 2021-10-20 |
| Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers KL1333 25 mg, KL1333 50 mg, KL1333 100 mg - MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies | Phase 1 | Completed | Yungjin Pharm. Co., Ltd. | 60 | 2017-06-26 | 2018-04-27 |
| A Dose-escalating Clinical Trial With KH176 KH176, placebo - MELAS, LHON | Phase 1 | Completed | Khondrion BV | 32 | 2015-05-01 | 2021-10-18 |
| Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose) - Mitochondrial Myopathy | Phase 1 / Phase 2 | Completed | Stealth BioTherapeutics Inc. | 36 | 2015-02-01 | 2019-12-27 |
Mitochondrial Diseases (9) · MELAS Syndrome (7) · Acidosis, Lactic (1) · Anxiety Disorders (1) · Cognition Disorders (1) · Deafness (1) · Diabetes Mellitus (1) · Dystonia (1) · Hearing Loss (1) · Kearns-Sayre Syndrome (1) · Leigh Disease (1) · MERRF Syndrome (1) · Migraine Disorders (1) · Mitochondrial Encephalomyopathies (1)
Metabolic Diseases (12) · Musculoskeletal Diseases (12) · Nervous System Diseases (12) · Neuromuscular Diseases (12) · Nutritional and Metabolic Diseases (12) · Muscular Diseases (11) · Brain Diseases (7) · Brain Diseases, Metabolic (7) · Brain Diseases, Metabolic, Inborn (7) · Cardiovascular Diseases (7) · Central Nervous System Diseases (7) · Cerebral Small Vessel Diseases (7) · Cerebrovascular Disorders (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7)
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (1) · Acetylcysteine (1) · Citrulline (1) · Exercise Test (1) · arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)
Children's Hospital of Philadelphia (4) · Abliva AB (1) · Baylor College of Medicine (1) · George Washington University (1) · Khondrion BV (1) · Maastricht University (1) · Michio Hirano, MD (1) · Stealth BioTherapeutics Inc. (1) · Yungjin Pharm. Co., Ltd. (1)
United States (8) · Belgium (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Anne Chiaramello, Ph.D. (1) · Debra Regier, M.D., Ph.D. (1) · Elizabeth M McCormick, MS (1) · Karin Faber, Prof. PhD MD (1) · Kyung-Sang Yu, MD., MBA (1) · Matilda Hugerth, MSc (1) · Michio Hirano, MD (1) · Wei-Liang Chen, M.D. (1) · Zarazuela Zolkipli-Cunningham (1) · Zarazuela Zolkipli-Cunningham, MBChB, MRCP (1) · Zuela Zolkipli-Cunningham, MBChB, MRCP (1)
U54NS078059 (3), UH3TR003897 (1)